Association of MiR-149 with Nutritional Risk Assessment and Postoperative Complications of Patients with Colorectal Cancer
PDF
HTML

Keywords

Colorectal cancer
Complications
MiR-149
Nutritional risk

How to Cite

Lin, L. ., Xu, F. ., Zhou, C. ., Quan, Z. ., & Jiang, H. (2021). Association of MiR-149 with Nutritional Risk Assessment and Postoperative Complications of Patients with Colorectal Cancer. Iranian Red Crescent Medical Journal, 23(12). https://doi.org/10.32592/ircmj.2021.23.12.1259

Abstract

Background: MiRNAs play an important role in the development of colorectal cancer (CRC); however, there is little evidence of miRNAs in the screening of the nutritional risks of patients with CRC.

Objectives: This study aimed to explore the role of preoperative miR-149 in nutritional screening of patients with CRC, and its associations with clinicopathological characteristics and postoperative complications of patients with CRC.

Methods: The associations of serum miR-149 with clinicopathological characteristics and postoperative complications of patients were analyzed in this study. The receiver operating characteristic curves were plotted with miR-149 as the test variable, the grouping results of the patients with nutritional risks (total NRS2002 score ≥3 points), and no nutritional risks (total NRS2002 score <3 points) based on the preoperative NRS2002 score as the state variables. The consistency of miR-149 and NRS2002 in the nutritional screening of CRC was analyzed using the Kappa test.

Results: MiR-149 was low in patients with CRC. There was a statistically significant difference in the miR-149 expression among patients with different tumor diameters and TNM stages in the two groups. The preoperative total NRS2002 score of CRC patients was <3 (without nutritional risks) in 271 cases, and ≥3 (with nutritional risks) in 129 cases. The sensitivity and specificity of miR-149 in the diagnosis of nutritional risks were 76.74% and 84.50%, respectively. The Kappa value was 0.622 with miR-149=3.095 as the critical value.

Conclusion: MiR-149 can reflect the preoperative nutritional status of patients with CRC, and miR-149=3.095 can be used as the cut-off point for nutritional risk screening of patients with CRC, which is an important index for assessing the nutritional risk in the preoperative period. The expression of miR-149 has a certain association with postoperative complications.

https://doi.org/10.32592/ircmj.2021.23.12.1259
PDF
HTML

References

  1. Jafarian AH, Forooshani MK, Takallou L, Roshan NM. CD10 expression in gastric carcinoma is correlated with tumor grade and survival. UnivMed. 2019;38(1):41-7. doi: http://dx.doi.org/10.18051.
  2. Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res. 2015;2015:1-16. doi: 10.1155/2015/158038. [PubMed: 26605342].
  3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. [PubMed: 25651787].
  4. van de Velde CJ. Surgery: palliative primary tumour resection in mCRC-debate continues. Nat Rev Clin Oncol. 2015;12(3):129-30. doi: 10.1038/nrclinonc.2015.7. [PubMed: 25601445].
  5. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol. 2005;11(11):1639-43. doi: 10.3748/wjg.v11.i11.1639. [PubMed: 15786541].
  6. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M, et al. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci. 2004;49(6):970-6. doi: 10.1023/b:ddas.0000034556.48527.6e. [PubMed: 15309885].
  7. Berindan-Neagoe I, Monroig PC, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64(5):311-36. doi: 10.3322/caac.21244. [PubMed: 25104502].
  8. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203-22. doi: 10.1038/nrd.2016.246. [PubMed: 28209991].
  9. Zhang G, Liu X, Li Y, Wang Y, Liang H, Li K, et al. EphB3-targeted regulation of miR-149 in the migration and invasion of human colonic carcinoma HCT116 and SW620 cells. Cancer Sci. 2017;108(3):408-18. doi: 10.1111/cas.13161. [PubMed: 28370854].
  10. Zhou W, Wang L, Miao Y, Xing R. Novel long noncoding RNA GACAT3 promotes colorectal cancer cell proliferation, invasion, and migration through miR-149. Onco Targets Ther. 2018;11:1543-52. doi: 10.2147/OTT.S144103.
  11. Ravasco P, Monteiro-Grillo I, Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr. 2012;96(6):1346-53. doi: 10.3945/ajcn.111.018838. [PubMed: 23134880].
  12. Mohammadi A, Mansoori B, Baradaran B. The role of microRNAs in colorectal cancer. Biomed Pharmacother. 2016;84:705-13. doi: 10.1016/j.biopha.2016.09.099. [PubMed: 27701052].
  13. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1766-74. doi: 10.1158/1055-9965.EPI-10-0027. [PubMed: 20551304].
  14. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61(5):739-45. doi: 10.1136/gut.2011.239236. [PubMed: 21930727].
  15. Lv ZC, Fan YS, Chen HB, Zhao DW. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for  colorectal cancer. Tumour Biol. 2015;36(3):1619-25. doi: 10.1007/s13277-014-2760-9. [PubMed: 25528214].
  16. Luo G, Chao YL, Tang B, Li BS, Xiao YF, Xie R, et al. miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F. Oncotarget. 2015;6(35):37808-23. doi: 10.18632/oncotarget.5676. [Pubmed: 26498692].
  17. Jin L, Li Y, Liu J, Yang S, Gui Y, Mao X, et al. Tumor suppressor miR-149-5p is associated with cellular migration, proliferation  and apoptosis in renal cell carcinoma. Mol Med Rep. 2016;13(6):5386-92. doi: 10.3892/mmr.2016.5205. [PubMed: 27121091].
  18. Yang D, Du G, Xu A, Xi X, Li D. Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4. Am J Cancer Res. 2017;7(11):2209-19.  [PubMed: 29218245].
  19. Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2015;35(2):499-515. doi: 10.1159/000369715. [PubMed: 25613903].
  20. Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K, et al. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol. 2002;28(4):396-400. doi: 10.1053/ejso.2002.1257. [PubMed: 12099649].
  21. Watanabe M, Iwatsuki M, Iwagami S, Ishimoto T, Baba Y, Baba H, et al. Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg. 2012;36(7):1632-9. doi: 10.1007/s00268-012-1526-z. [PubMed: 22407085].
  22. Sorensen J, Kondrup J, Prokopowicz J, Schiesser M, Krahenbuhl L, Meier R, et al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin Nutr. 2008;27(3):340-9. doi: 10.1016/j.clnu.2008.03.012. [PubMed: 18504063].
  23. Schiesser M, Muller S, Kirchhoff P, Breitenstein S, Schafer M, Clavien PA, et al. Assessment of a novel screening score for nutritional risk in predicting complications in gastro-intestinal surgery. Clin Nutr. 2008;27(4):565-70. doi: 10.1016/j.clnu.2008.01.010. [PubMed: 18342995].
  24. Wang Y, Zheng J, Gao Z, Han X, Qiu F. Investigation on nutritional risk assessment and nutritional support status of surgical patients with colorectal cancer. J Buon. 2018;23(1):62-7. [PubMed: 29552761].